Therapies for the treatment of metastatic cancers

Volastra Therapeutics is focused on developing innovative cancer therapies that specifically target chromosomal instability (CIN), a characteristic of many cancers that leads to increased genetic diversity and treatment resistance. The company leverages its proprietary CINtech research strategy, which combines advanced screening techniques and computational modeling to identify and characterize CIN-specific targets. This approach allows Volastra to match these targets with new biomarkers, enhancing the selection of patients who may benefit from their therapies. By utilizing large oncology data sets, Volastra aims to uncover novel insights into cancer cell vulnerabilities, thereby advancing its understanding of CIN and its implications for therapeutic development.

Central to Volastra's therapeutic strategy are its KIF18A inhibitors, which are designed to exploit the unique reliance of chromosomally unstable cancer cells on this protein for successful cell division. KIF18A plays a critical role in the alignment of chromosomes during mitosis, and its inhibition can disrupt this process, leading to cancer cell death while sparing normal cells. Volastra is advancing two differentiated KIF18A inhibitors through clinical trials, with the goal of providing new treatment options for patients with challenging cancer types, such as high-grade serous ovarian cancer. This targeted approach not only aims to improve patient outcomes but also represents a significant advancement in the understanding and treatment of cancers characterized by chromosomal instability.

United States

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline.  Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1  clinical trials for cancers with high levels of chromosomal instability.

Volastra Therapeutics

Company Details